Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Early HER2-positive breast cancer
What changed

Early HER2-positive breast cancer

What changed: Early HER2-positive breast cancer

Cancer page →

Every dated change on the records linked to Early HER2-positive breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Trial result12Milestone10This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordEarly HER2-positive breast cancer
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 3

2025Trial resultDESTINY-Breast05
DESTINY-Breast05 reported
3-year iDFS 92.
2025Trial resultDESTINY-Breast11
DESTINY-Breast11 reported
pCR 67.
2025MilestoneDESTINY-Breast05
DESTINY-Breast05 and DESTINY-Breast11
A milestone in how this cancer is treated.

2024 · 2

2024Trial resultPHERGain
PHERGain reported
3-year iDFS 95.
2024MilestonePHERGain
PHERGain: PET-guided omission of chemotherapy
A milestone in how this cancer is treated.

2021 · 1

2021Trial resultATEMPT
ATEMPT reported
Very high three-year invasive disease-free survival with one year of trastuzumab emtansine in stage I disease, but clinically relevant toxicity was not lower than with paclitaxel plus trastuzumab.

2019 · 2

2019Trial resultPERSEPHONE
PERSEPHONE reported
4-year DFS 89.
2019MilestonePERSEPHONE
PERSEPHONE: six months of trastuzumab nearly as good as twelve
A milestone in how this cancer is treated.

2018 · 4

2018Trial resultKATHERINE
KATHERINE reported
iDFS HR 0.
2018Trial resultKRISTINE
KRISTINE reported
Pathological complete response 44.
2018Trial resultTRAIN-2
TRAIN-2 reported
Pathological complete response 67% without anthracycline vs 68% with; 3-year event-free survival 93.
2018MilestoneKATHERINE
KATHERINE, TRAIN-2 and KRISTINE
A milestone in how this cancer is treated.

2017 · 2

2017Trial resultAPHINITY
APHINITY reported
8-year iDFS HR 0.
2017MilestoneAPHINITY
APHINITY: adjuvant pertuzumab helps node-positive disease
A milestone in how this cancer is treated.

2015 · 1

2015Trial resultAPT (adjuvant paclitaxel-trastuzumab)
APT (adjuvant paclitaxel-trastuzumab) reported
7-year DFS 93%; 10-year RFI 96.

2013 · 1

2013MilestonePertuzumab
Pertuzumab: first approval granted on a pathological complete response endpoint
A milestone in how this cancer is treated.

2012 · 2

2012Trial resultNeoSphere
NeoSphere reported
Pertuzumab added to trastuzumab and docetaxel raised the pathological complete response rate in HER2-positive breast cancer; neoadjuvant pertuzumab received accelerated approval in September 2013.
2012MilestonePertuzumab
NeoSphere: pertuzumab raises pathological complete response
A milestone in how this cancer is treated.

2005 · 2

2005Trial resultHERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)
HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab) reported
B-31/N9831 10-year OS 84% vs 75.
2005MilestoneHERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)
HERA, NSABP B-31 and N9831: a year of adjuvant trastuzumab
A milestone in how this cancer is treated.

1998 · 1

1998MilestoneTrastuzumab
Trastuzumab approved for metastatic disease
A milestone in how this cancer is treated.

1987 · 1

1987MilestoneEarly HER2-positive breast cancer
Slamon: HER2 amplification marks aggressive disease
A milestone in how this cancer is treated.